Antiangiogenic cancer drug drives lymphangiogenic metastasis.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28179505.
- Also identified by DOI 10.1126/scitranslmed.aam6060.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor blood vessel-destroying cancer drug induces development of tumor lymphatics that contribute to treatment failure.
Medical subject headings
- Carcinoma, Renal Cell
- Kidney Neoplasms